NEW YORK, April 14, 2014 /PRNewswire/ -- Cord Blood Banking leader Americord today published a bill of rights it believes every cord blood banking client should expect to receive from their cord blood bank. Encompassing information as well as service, the "Cord Blood Banking Bill of Rights" covers fundamental issues such as transparency and equitable pricing and ensures that clients who are storing their cord blood, cord tissue, or placenta tissue receive the best service possible.
"We believe strongly that clients are entitled to the highest quality of service," said Americord CEO Martin Smithmyer. "This begins with the clarity and accuracy of the information clients get from Americord about cord blood banking in general, and continues through every step of enrollment, collection, and storage of their baby's stem cells."
Among other issues, Americord's Bill of Rights calls for transparency around the widespread practice of cord blood banks paying doctors for referrals to their clients. Smithmyer has explicitly denounced this practice, which Americord does not engage in, saying that is it not only unethical, but also a driver behind the high cost of cord blood banking.
Find the Cord Blood Banking Bill of Rights at http://cordadvantage.com/about-us/cord-blood-banking-bill-of-rights.html.
About Americord Registry
Americord is a leader in the advancement of umbilical cord blood, cord tissue and placenta tissue banking. Americord collects, processes, and stores newborn stem cells from umbilical cord blood for future medical or therapeutic use, including the treatment of more than 80 blood diseases such as sickle cell anemia and leukemia. Founded in 2008, Americord is registered with the FDA and operates in all 50 states. The company's laboratory is CLIA Certified, accredited by the AABB and complies with all federal and state guidelines and applicable licenses. Americord is headquartered in New York, NY. You may visit Americord's website at cordadvantage.com for more information. You may also find Americord on Facebook and follow the company on Twitter.
SOURCE Americord Registry